Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of MagForce AG

Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief 
Executive Officer of MagForce AG 
BERLIN -- (Marketwired) -- 06/14/13 --  The Supervisory Board of
Magforce AG (Frankfurt, XETRA: MF6), a leading medical device company
in the field of oncology, has appointed Dr. Ben J. Lipps, former CEO
and Chairman of Fresenius
Medical Care, as Chairman of the Management
Board and Chief Executive Officer of the company starting September
2013. While serving as Chairman and CEO of Magforce, Ben Lipps will
continue his consultantship with Fresenius Medical Care. The current
management board members of Magforce Prof. Dr. Hoda Tawfik
(Chief
Developement & Medical Officer) and Christian von Volkmann (Chief
Financial Officer) remain in their respective position. 
Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the
Management
Board of Fresenius Medical Care in May 1999. In December
2012, he stepped down
as Chairman of the Management Board and CEO.
Dr. Lipps led the research team
that developed the first commercial
hollow fiber artificial kidney at the end of the 1960's. Today over
two million dialysis patients rely on hollow fiber dialyzers for life
sustaining treatments. 
Norbert Neef, Chairman of the Supervisory Board of MagForce,
comments: "MagForce
is very proud to have attracted a former DAX 30
CEO as addition to MagForce's
management team. Dr. Lipps will help us
harvesting the full potential of our
great IP. Based on the already
existing regulatory approval for our NanoTherm(R)
Therapy for all
forms of brain cancer we are confident to be able to develop
MagForce
into a global medical device company successfully targeting the
treatment of multiple cancer forms." 
Ben Lipps comments: "MagForce is a most interesting opportunity in
the medical
device and pharma world. Globally, over two million
patients are diagnosed with
brain, head & neck, and prostate cancers
each year. Clearly, the NanoTherm(R)
Therapy being developed by
MagForce AG can be applied as an adjunct or as a monotherapy to
assist in the treatment regiments for these solid tumors.
NanoTherm(R) Therapy has regulatory approval in 27 European countries
already. I am looking forward to work with the very competent and
highly motivated management team at MagForce. Our focus will be to
advance this therapy to the
next level with its widespread
commercialization and to building a global player
in the area of
cancer treatment for the good of patients". 
About MagForce AG 
MagForce AG is a leading medical device company in the field of
nanomedicine in oncology, listed in the entry standard (MF6). The
Company's proprietary, NanoTherm(R) therapy, enables the targeted
treatment of solid tumors through the intratumoral generation of heat
via activation of superparamagnetic nanoparticles. NanoTherm(R),
NanoPlan(R), and NanoActivator(TM) are components
of the therapy and
have received EU-wide regulatory approval as medical devices
for the
treatment of brain tumors. MagForce, NanoTherm(R), NanoPlan(R), and
NanoActivator(TM) are trademarks of MagForce AG in selected
countries. For more
information, please visit www.magforce.com. 
Full Resume Dr. Ben Lipps 
Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the
Management
Board of Fresenius Medical Care in May 1999. In December
2012 he stepped down as Chairman of the Management Board and CEO.
During his term, Fresenius Medical
Care's sales tripled from 3.8 to
12.8 billion dollars, and the annual net profit
grew 6 times to 1.1
billion dollars. 
He was also Chief Executive Officer of Fresenius Medical Care North
America until February 2004. He was President, Chief Executive
Officer, Chief Operating
Officer and a director of Fresenius USA from
October 1989 through February 2004, and served in various capacities
with Fresenius USA's predecessor from
1985 through 1989. 
He earned his master's and doctoral degrees at the Massachusetts
Institute of
Technology in chemical engineering. Before joining the
Fresenius Group in 1985,
Dr. Lipps held several research management
positions in various companies, among
them with DOW Chemical. 
Disclaimer 
This release may contain forward-looking statements and information
which may be identified by formulations using terms such as "expects",
"aims", "anticipates",
"intends", "plans", "believes", "seeks",
"estimates" or "will". Such forward-looking statements are based on
our current expectations and certain
assumptions, which may be
subject to a variety of risks and uncertainties. The
results actually
achieved by MagForce AG may substantially differ from
these
forward-looking statements. MagForce AG assumes no obligation
to update these
forward-looking statements or to correct them in case
of developments, which
differ from those, anticipated. 
MagForce_Press Release_June 14, 2013:
http://hugin.info/143761/R/1709683/566682.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and 
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
originality of the information contained therein. 
Source: MagForce AG via Thomson Reuters ONE 
[HUG#1709683] 
For further information:
Anne Hennecke
MC Services AG
anne.hennecke@mc-services.eu
P +49 89 210 228 18
F +49 89 210 228 88
M +49 151 12 555 759
 
 
Press spacebar to pause and continue. Press esc to stop.